Vaccine research organizations recently announced a new program in Kenya, Rwanda, and the Democratic Republic of Congo to evaluate the safety and immunogenicity of homologous and heterologous COVID-19 vaccine booster regimens in people living with Human immunodeficiency virus (HIV).
The Coalition for Epidemic Preparedness Innovations (CEPI) and the Kenya-based Victoria Biomedical Research Institute (VIBRI) confirmed on May 11, 2022, that about $12.5 million in funding would be deployed to assess this “mix and match” booster approach in HIV populations.
Do HIV and COVID-19 Vaccines Mix?
Self-Reported Postpartum Depressive Symptoms Up During Pandemic
States with greater increases in symptoms had fewer deaths from COVID-19 and lower women’s unemployment rates
Previous Myocardial Injury Tied to Worse COVID-19 Outcomes
Significant but weaker associations with selected adverse outcomes seen for preexisting hypertension, diabetes, and ischemic heart disease
2019 to 2020 Saw Increase in Overall Firearm Homicide Rates
Largest increases seen among non-Hispanic Black males aged 10 to 44 years and in American Indian, Alaska Native males aged 25 to 44 years
Health Improves Over Two Years for COVID-19 Hospitalization Survivors
Improvements seen in physical and mental health, but survivors still have more symptoms than controls at two years
‘Tragic Milestone’: One Million American Lives Lost to COVID-19
President Biden has ordered U.S. flags to be flown at half-staff in honor of those lost